SCHEMBL24393178

SCHEMBL24393178

CC(C)(C)OC(=O)Nc1ccc(F)c(Oc2nc(Cl)ncc2Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 1/20 0.43
▸ EGFR P00533 2/20 0.42
▸ AURKB Q96GD4 1/20 0.42
▸ STK17B O94768 1/20 0.42
▸ STK17A Q9UEE5 1/20 0.42
▸ MAPKAPK2 P49137 3/20 0.41
▸ MAPT P10636 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ GRM4 Q14833 2/20 0.39
▸ P2RX3 P56373 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ MAP4K4 O95819 1/20 0.39
▸ RORC P51449 1/20 0.39
▸ RAF1 P04049 1/20 0.38
▸ BRAF P15056 1/20 0.38
▸ KDR P35968 2/20 0.38
▸ MET P08581 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29537896 1.00 SYK (0.43) SYKEGFRAURKBSTK17BSTK17A
SCHEMBL4171563 0.82 EGFR (0.48) SYKEGFRSTK17BSTK17AMAPT
SCHEMBL29537662 0.82 BTK (0.53) EGFR
SCHEMBL24392927 0.82 BTK (0.53) EGFR
SCHEMBL29537978 0.82 MAPK1 (0.54) SYKSTK17AMAP4K4KDR
SCHEMBL16524048 0.80 STK17B (0.48) SYKEGFRAURKBSTK17BSTK17A
SCHEMBL13166463 0.78 SYK (0.51) SYKEGFRMEN1KMT2ARAF1
SCHEMBL3202901 0.76 HTT (0.62) EGFRAURKBMAPTKDM4EMEN1
SCHEMBL16524060 0.76 STK17B (0.48) SYKEGFRAURKBSTK17BSTK17A
SCHEMBL24393264 0.74 SYK (0.45) SYKEGFRAURKBSTK17BSTK17A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240051945-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF BLUEPRINT MEDICINES CORPORATION 2024-02-15 — — US disclosed
EP-4237418-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF Blueprint Medicines Corporation (US) 2023-09-06 — — EP disclosed
WO-2022094354-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF LENGO THERAPEUTICS, INC. (US) 2022-05-05 — — WO disclosed
WO-2022094354-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF LENGO THERAPEUTICS, INC. (US) 2022-05-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240051945-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF TYMP, DPYD, TYMS SYK 1817/4885EGFR 4504/4885AURKB 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback